Journal
ORAL ONCOLOGY
Volume 52, Issue -, Pages 1-10Publisher
ELSEVIER
DOI: 10.1016/j.oraloncology.2015.11.009
Keywords
OX40; Oral cancer; Head and neck cancer; Immunotherapy; PD-1; CTLA-4
Categories
Funding
- Oral and Maxillofacial Surgery Foundation Research Support Grant
- Chiles foundation
- Robert W. and Elsie Franz foundation
- Wes and Nancy Lematta foundation
- Lynn and Jack Loacker foundation
Ask authors/readers for more resources
OX40 is a member of the tumor necrosis factor (TNF) receptor family and a potent co-stimulatory pathway that when triggered can enhance T-cell memory, proliferation and anti-tumor activity in patients with metastatic cancer. Ongoing investigations at our institution have demonstrated that OX40 expressing T cells are found in abundance in the tumors of patients with advanced stage head and neck squamous cell carcinoma (HNSCC). This has led to the initiation of human clinical trials investigating OX40-directed therapy for patients with HNSCC in both the metastatic and curative setting. The purpose of this review is to explore what is known about OX40 signaling and discuss how this pathway potentially can be modulated to improve outcome for patients with HNSCC. (C) 2015 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available